| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 1.30 | -0.06 (-4.41%) | 1.18 - 3.96 | 11.4 million (Above Avg) |
Market data as of 4:00PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 1.28 |
|---|---|
| Previous Close | 1.36 |
| Day's Range | 1.27 - 1.32 |
| Market Cap | 12.9M |
| Avg Volume (10 Day) | 1.3M |
| Price/Earnings (Trailing 12 Mo.) | 0.2x |
| Earnings Per Share (Trailing 12 Mo.) | 5.45 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Pass |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Venaxis Announces Pricing of Offering of Common Stock and Warrants
PR Newswire - Thursday 05/23/2013 7:03 PM ET
| APPY | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -57.70% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.32 | |
| LT Debt/Equity | 0.09 | |
| Earnings Yield | 500.00% | |
| Price/Sales | 176.04 |
| Company | Last | Change |
|---|---|---|
| ImmuCell Corp | 3.65 | 0.00% |
| Palatin Technologies Inc | 0.64 | +1.59% |
| Rosetta Genomics Ltd | 4.01 | +0.50% |
| Chembio Diagnostics Inc | 4.50 | 0.00% |
| Vermillion Inc | 3.08 | 0.00% |
Data is delayed by at least 15 min.